AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33249593
Drug: high-dose rhIGF‐1/rhIGFBP‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose rhIGF‐1/rhIGFBP‐3 (60 mg/day)
Trial: 33249593
Drug: low-dose rhIGF‐1/rhIGFBP‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose rhIGF‐1/rhIGFBP‐3 (30 mg/day)
Trial: 35462371
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g once daily during the maintenance phase
Trial: 36043350
Drug: Fluoxetine 10
RxNorm normalized name: fluoxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10 mg once daily for 12 weeks
Trial: 32632763
Drug: Face-to-face treatment
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatment (10 sessions, 60 minutes each)
Trial: 32632763
Drug: Low-intensity treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity treatment (information delivered in printed or electronic format, supported by up to four telephone sessions)
Trial: 35450913
Drug: Complex continuum
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex continuum of care intervention delivered by community health workers, including health literacy material, multimicronutrient supplement, health services, feedback, and behaviour change support sessions.
Trial: 35062988
Drug: Naoxintong capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxintong capsules (NXT)
Trial: 32007169
Drug: Pharmacological cardioversion
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological cardioversion followed by electrical cardioversion (drug-shock)
Trial: 32007169
Drug: Drug infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug infusion only (part of drug-shock group)
Trial: 34896904
Drug: Probiotics (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (three capsules, twice/day)
Trial: 32643886
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium double-release enteric-coated capsules and Fugui Gutong capsules
Trial: 33010112
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg orally twice daily)
Trial: 36049050
Drug: Gut microbiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiome L-tryptophan biosynthesis during acute COVID-19
Trial: 36167574
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia with sevoflurane
Trial: 35150590
Drug: Denture disinfecting
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture disinfecting tablets
Trial: 35150590
Drug: Denture disinfecting
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture disinfecting tablets plus palatine mucosa brushing solution
Trial: 32448992
Drug: Wheat soya
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat soya blend plus (WSBP) provided during pregnancy and lactation (5 kg/month, 165 g/day)
Trial: 32827193
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (topical corticosteroids + antibiotics)
Trial: 32827193
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids treatment
Trial: 34369693
Drug: Donepezil, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil, 5 mg once a day for 4 weeks
Trial: 32592571
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy (SVT) + transcerebral magnetotherapy
Trial: 32592571
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy (SVT)
Trial: 34976102
Drug: Lateral Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral Direct Anterior Approach (L-DAA)
Trial: 33067484
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all MRI sequences excluding ADC map
Trial: 32545250
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation of 400 IU/day
Trial: 38886836
Drug: Bevacizumab-based chemotherapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab-based chemotherapy
Trial: 32671536
Drug: Nasogastric tube
RxNorm normalized name: nasogastric tube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasogastric tube with Gastrografin (NGT-G)
Trial: 32445474
Drug: Intrapartum oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum oral azithromycin
Trial: 32512963
Drug: AHH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHH group (6% hydroxyethyl starch 130/0.4 at a rate of 20 ml/min after anesthesia induction)
Trial: 35201607
Drug: Extended-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release methylphenidate
Trial: 35988587
Drug: CYP2C19 genotype-guided
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotype-guided antithrombotic treatment (clopidogrel 75 mg for normal metabolizers, clopidogrel 150 mg for intermediate metabolizers, acetylsalicylic acid 80 mg plus rivaroxaban 2.5 mg for poor metabolizers)
Trial: 35988587
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily (control group)
Trial: 35988587
Drug: CYP2C19 genotype-guided
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotype-guided antithrombotic treatment
Trial: 35379380
Drug: Prophylactic amoxicillin‐clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic amoxicillin‐clavulanic acid (0.375 mg/mL) for 14 days
Trial: 35379380
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of C. bovis inoculation and oral antibiotics (Cb+Abx+)
Trial: 32868370
Drug: Antibody
RxNorm normalized name: Antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody
Trial: 34187478
Drug: Genetically mimicking
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically mimicking PCSK9 inhibitors or ezetimibe
Trial: 39425917
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion
Trial: 34482319
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C and thiamine for 48 hours
Trial: 35503768
Drug: Cycling (altering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycling (altering first-line empiric therapy for Gram-negative bacteria every other 6-weeks)
Trial: 35503768
Drug: Mixing (changing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixing (changing antibiotic type every empiric antibiotic course)
Trial: 36253903
Drug: Low-fat, vegan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, vegan diet and cooked soybeans (½ cup [86 g] daily)
Trial: 32394874
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with liposomal amphotericin B (7.5 mg/kg, single dose) and short-course miltefosine (2.5 mg/kg/day for 14 days)
Trial: 32394874
Drug: Miltefosine monotherapy
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine monotherapy (2.5 mg/kg/day for 28 days)
Trial: 35939920
Drug: V‐NeST plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V‐NeST plus treatment as‐usual (TAU)
Trial: 33914314
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg) + 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Trial: 33914314
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Trial: 35313167
Drug: Adjuvant pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant pertuzumab (P) added to trastuzumab and chemotherapy
Trial: 35313167
Drug: Placebo (Pla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Pla) added to trastuzumab and chemotherapy
Trial: 32859662
Drug: Tailored multistep
RxNorm normalized name: MultiStem
DrugBank: MultiStem (DB15742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored multistep intervention (IA) incorporating electronic PRO assessment, case vignette, and expert-consented treatment recommendations
Trial: 35551600
Drug: AD036 (atomoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD036 (atomoxetine 80 mg and oxybutynin 5 mg)
Trial: 35551600
Drug: Atomoxetine 80
RxNorm normalized name: atomoxetine 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 80 mg alone
Trial: 34238537
Drug: Adapted glass
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted glass fiber post with post space preparation of the same size
Trial: 33004790
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g whey protein drink (120 kcal)
Trial: 32346686
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ZOL with calcitriol and calcium carbonate
Trial: 32346686
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ZOL with calcium carbonate (control)
Trial: 34363831
Drug: Valacyclovir (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (2 g immediate dose followed by 500 mg, twice a day, for 3 days) + Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days)
Trial: 34363831
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days) + Placebo
Trial: 36416302
Drug: Proposed model
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed model for assessing treatment effect heterogeneity over exposure time
Trial: 36416302
Drug: Permutation test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permutation test for the variance component of the heterogeneous treatment effect parameters
Trial: 36039009
Drug: solution-focussed education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution-focussed education and counselling
Trial: 34531878
Drug: Janus kinase
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janus kinase (JAK) inhibitors for acute and chronic graft‐versus‐host disease (GVHD) and cytokine release syndrome (CRS)
Trial: 34531878
Drug: Janus kinase
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janus kinase (JAK) inhibitors
Trial: 34887529
Drug: 10 mg/10
RxNorm normalized name: bisacodyl 10 mg/10 mL RECTAL ENEMA (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/10 mg OLZ/SAM for 21 days
Trial: 34887529
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg olanzapine for 21 days
Trial: 33685474
Drug: Melatonin soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin soft gelatin capsule (5 mg twice a day for 7 days) along with standard treatment for COVID-19.
Trial: 33685474
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education’s protocol for 7 days.
Trial: 34898011
Drug: Self-monitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring and feedback (SM+FB) with access to a customized smartphone application providing three daily feedback messages.
Trial: 33711941
Drug: Personalized Hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized Hypertension Management (PHMA) intervention package including support for self-monitoring, supervised machine communications, daily education or reminder messages, weekly blood pressure notification, and quarterly signed feedback.
Trial: 35768902
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg non-enteric coated aspirin for 1 week (NYU cohort)
Trial: 35768902
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Trial: 35768902
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Trial: 35768902
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 81 mg and 325 mg non-enteric coated aspirin (Duke cohort)
Trial: 38249987
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic
Trial: 35906990
Drug: Extended pre-quit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended pre-quit varenicline treatment
Trial: 35906990
Drug: Standard pre-quit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pre-quit varenicline treatment
Trial: 36512069
Drug: Sivopixant 150
RxNorm normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivopixant 150 mg
Trial: 34119469
Drug: Therapy withdrawal
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy withdrawal
Trial: 34119469
Drug: Control (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (continued therapy)
Trial: 35623995
Drug: Minimalist hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minimalist hypnotic music with guided relaxation breathing (MHMGRB) (Group II, n=40)
Trial: 32723722
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support for 21 days.
Trial: 34291584
Drug: Insulin degludec/aspart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/aspart (IDegAsp)
Trial: 34291584
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (control)
Trial: 34818588
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation intervention (motivational interviewing sessions, 2 weeks of nicotine replacement therapy)
Trial: 33719579
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg twice daily for 7 days)
Trial: 33719579
Drug: Placebo (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7 days of treatment)
Trial: 33235447
Drug: Aerosol-inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol-inhaled amikacin
Trial: 35305906
Drug: Paclitaxel-Coated Balloon
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-Coated Balloon (PCB) (SeQuent Please, B. Braun Melsungen; 3 μg/mm2)
Trial: 35305906
Drug: Sirolimus-Coated Balloon
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus-Coated Balloon (SCB) (SeQuent SCB, B. Braun Melsungen; 4 μg/mm2)
Trial: 33026766
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide topical solution, 45% (HP45)
Trial: 34529025
Drug: Carfilzomib, Lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by Lenalidomide maintenance therapy
Trial: 33874968
Drug: Yarrow liver
RxNorm normalized name: YARROW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yarrow liver compresses applied externally once daily during radiation therapy (RT)
Trial: 33874968
Drug: Palliative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiation therapy (RT) alone
Trial: 35820664
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid HIV self-test
Trial: 33506314
Drug: Oral calcifediol
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcifediol 20 µg/day
Trial: 33506314
Drug: Oral calcifediol
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcifediol 30 µg/day
Trial: 35809362
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (TE2)
Trial: 32390168
Drug: ICI monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI monotherapy (nivolumab: 44.3%, pembrolizumab: 11.7%, ipilimumab: 23.6%)
Trial: 32390168
Drug: ICI combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI combination therapy
Trial: 32699287
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (HW) 1.5 L/d for 4 weeks
Trial: 32565465
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299v probiotic therapy in addition to usual care
Trial: 33528922
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 to 1.5 μg/kg/hour)
Trial: 33528922
Drug: Propofol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (5 to 50 μg/kg/min)
Trial: 32299733
Drug: G-Series media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Series media system with antioxidants (A3 group)
Trial: 32299733
Drug: G-Series media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Series media system (control)
Trial: 35404772
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of sedatives
Trial: 33970327
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (CF) 400 mg for 7 days
Trial: 37194813
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection technique
Trial: 33959750
Drug: Inoculant (INO)
RxNorm normalized name: Fusisporium inosculans
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculant (INO) containing Lactobacillus buchneri and Pediococcus pentosaceus (4 × 10^5 and 1 × 10^5 cfu/g of fresh corn)
Trial: 36229117
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (iSOMA guided and iSOMA-GoD)
Trial: 34237458
Drug: Experimental placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental placebo manipulations (e.g., positive expectations, time spent with subjects, training for accurate symptom reporting)
Trial: 32000687
Drug: Both LC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both LC and CC
Trial: 33917922
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy
Trial: 36326471
Drug: Prazosin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.05 mg/kg)
Trial: 32041632
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient children (serum 25(OH)D < 12 ng/ml)
Trial: 32041632
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D inadequate children (serum 25(OH)D 12-20 ng/ml)